In this episode, Urology Times® Assistant Editor Janelle Hart spoke with Karim Fizazi, MD, PhD, about results from a game-changing study that was presented at the 2022 ASCO Genitourinary Cancers Symposium. The phase 3 ARASENS trial improved overall survival in patients with metastatic hormone-sensitive prostate cancer with triplet therapy. Fizazi is a medical oncologist and head of the department of cancer medicine at the Institute of Gustave Roussy, and professor of oncology at the University of Paris Sud in Villejuif, France.